Seattle Ranks 9th in Top 10 U.S. Biopharma Clusters 


Seattle is ranked ninth in GEN’s 2023 rankings for the top 10 biopharma clusters across the country. Over the past year, major biotech moves including Pfizer’s $43 billion acquisition of Seagen have made the city a front runner in biotech innovation. 

Rankings are determined by five factors: NIH funding, patent counts, lab space, venture capital funding and workforce size. Seattle ranks seventh in venture capital, eighth in NIH funding, ninth in lab space and tenth in both patents and jobs.  

Washington holds over 300 life science sites that supply over 100,000 jobs. From 2015-2021, the state’s industry saw a 33.6% increase in job growth and an annual economic impact of $35.5 billion.